Oncotarget

Clinical Research Papers:

Clinical study of 99mTc-3P-RGD2 peptide imaging in osteolytic bone metastasis

Guoqiang Shao, Wei Gu, Muhong Guo, Shiming Zang, Jinjing Fu, Shuang Liu, Feng Wang and Zizheng Wang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:75587-75596. https://doi.org/10.18632/oncotarget.17486

Metrics: PDF 971 views  |   HTML 1429 views  |   ?  


Abstract

Guoqiang Shao1, Wei Gu2, Muhong Guo1, Shiming Zang1, Jinjing Fu1, Shuang Liu3, Feng Wang1 and Zizheng Wang1

1 Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China

2 Department of Respiration, Nanjing First Hospital, Nanjing Medical University, Nanjing, China

3 School of Health Sciences, Purdue University, West Lafayette, IN, USA

Correspondence to:

Zizheng Wang, email:

Feng Wang, email:

Keywords: osteolytic metastasis; targeted imaging; integrin αvβ3; RGD peptide; lung cancer

Received: January 06, 2017 Accepted: April 04, 2017 Published: April 27, 2017

Abstract

Objective: To investigate the value of integrin αvβ3 targeted imaging with 99mTc-HYNIC-PEG4-E[PEG4-c(RGDfk)]2 (99mTc-3P-RGD2) as a radiotracer in dectecting osteolytic bone metastases.

Methods: This is a retrospective study involving a cohort of 69 consecutive patients including 59 with lung cancer and 10 with other cancers. Patients were required to receive whole body scan (WBS) and regional SPECT/CT imaging with 99mTc-3P-RGD2 (RGD imaging) and 99mTc-MDP (MDP imaging) as a radiotracer successively within days. Final diagnosis was based on comprehensive assessment of all available data including case history, CT, MRI, SPECT/CT, PET/CT, histopathology and 6-12 months follow-up. Visual observation and semiquantitative analysis (T/N: tracer uptake ratio of osteolytic metastases to normal bone) of 99mTc-3P-RGD2 or 99mTc-MDP imaging were performed and their detective values for osteolytic metastases were compared.

Results: A total of 131 osteolytic metastatic lesions were retrospectively studied. Osteolytic metastases mainly presented as “hot region”, occasionally as “cool or normal region” on RGD imaging. The detection sensitivity of RGD WBS for osteolytic metastases was significantly higher than that of 99mTc-MDP WBS (80.9% vs. 46.6%, p<0.01). The sensitivity increased to 96.2% (126/131) when combining with SPECT/CT. 99mTc-3P-RGD2 imaging also promoted the detection of unknown primary tumor, lymph node metastases and offered information for clinical staging. T/N of 99mTc-3P-RGD2 in lung adenocarcinoma osteolytic metastases showed no statistical difference compared with that in squamous-cell carcinoma (6.84±3.46 vs. 7.33±3.22, t = 0.39, p = 0.71). Whereas, it was higher in osteolytic metastases from lung cancer than that from thyroid cancer (7.05±3.01 vs. 4.11±2.67, p = 0.03). Conclusion: 99mTc-3P-RGD2 peptide imaging showed great potential for detection of osteolytic bone metastasis due to high expression level of integrin αvβ3 on osteoclast and most tumor cells.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17486